64 #AHA24 | scientificsessions.org *Not a CE accredited session. Evidence-Based Strategy for the Treatment of Recurrent Pericarditis 12:30-1:15 p.m. | Heart Theater I SUPPORTER: Kiniksa Pharmaceuticals Corp. Exploring the Next Chapter in the Groundbreaking CRISPR Journey: Getting to the Heart of the Matter 12:30-1:15 p.m. | Learning Studio I SUPPORTER: Intellia Therapeutics, Inc Finding Lp(a): “little” Things, Big Consequences 12:30-1:15 p.m. | Learning Studio II SUPPORTER: Novartis Pharmaceutical Corporation Lipid Medication Adherence and Clinician Hesitation in Patients With ASCVD 12:30-1:15 p.m. | Heart Theater II SUPPORTER: AHA Quality, Outcomes, Research, & Analytics (QORA) GenePHIT: A novel AAV Gene Therapy Trial in Congestive Heart Failure 1:30-2:00 p.m. | CardioTalk II SUPPORTER: Asklepios BioPharmaceutical, Inc. Jardiance® (empagliflozin) Tablets: Expert Perspectives on Clinical Trial Data and Approved Indications 1:45-2:30 p.m. | Learning Studio I SUPPORTER: Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA Lowering LDL-C for Very High-Risk ASCVD Patients: What You Need to Know 1:45-2:30 p.m. | Learning Studio II SUPPORTER: Amgen Inc ViVE and Let Thrive: Revolutionizing Virtual Care With Equity at Heart 3-3:30 p.m. | CardioTalk II SUPPORTER: AHA Center for Telehealth Coronary Inflammation: Shaping the Future of Long-Term Cardiovascular Risk Reduction 3:15-4 p.m. | Learning Studio I SUPPORTER: Caristo Diagnostics Emerging Clinical Landscape in ATTR-CM 3:15-4 p.m. | Learning Studio II SUPPORTER: BridgeBio Pharma, Inc Sunday, Nov. 17 Navigating the Complexities of Hypertrophic Cardiomyopathy (HCM): Addressing Delayed Diagnosis, Disease Burden and Shared Decision-Making 9:30-10:15 a.m. | Learning Studio I SUPPORTER: Cytokinetics, Inc Moving Beyond Clinical Trials: Understanding Real-World Evidence in Venous Thrombosis (VTE) 9:30-10:30 a.m. | Learning Studio II SUPPORTER: Bristol-Myers Squibb – Pfizer Eliquis A New Era in the Treatment of Hypertension 9:45-10:15 a.m. | CardioTalk II SUPPORTER: Idorsia Pharmaceuticals Ltd Antiarrhythmic Drugs in Atrial Fibrillation: Putting the Guideline Into Practice 11:15 a.m.-12 p.m. | Learning Studio I SUPPORTER: Sanofi Evaluating Long-Term Outcomes and Real-World Impact of Cardiac Myosin Inhibition in Adults With Symptomatic NYHA Class II-III Obstructive HCM 11:15 a.m.-12 p.m. | Heart Theater I SUPPORTER: Bristol-Myers Squibb Managing LDL-C With LEQVIO® (inclisiran) After a Recent Coronary Event: Putting Evidence Into Practice 11:15 a.m.-12 p.m. | Learning Studio II SUPPORTER: Novartis Pharmaceutical Corporation A New Era in the Treatment of Hypertension 11:15 a.m.-12 p.m. | Heart Theater II SUPPORTER: Idorsia Pharmaceuticals Ltd A Development for Adults With Pulmonary Arterial Hypertension 12:30-1:15 p.m. | Learning Studio I SUPPORTER: Merck & Co. Address the Gap: Elevate Care for CVD With Urgent LDL-C Management 12:30-1:15 p.m. | Learning Studio II SUPPORTER: Amgen Inc GDMT and Hyperkalemia: A Crossroad for Cardiology, Finding an Optimal Path 12:30-1:15 p.m. | Heart Theater I SUPPORTER: AstraZeneca Saturday, Nov. 16, Industry Events continued
RkJQdWJsaXNoZXIy MjI2NjI=